Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. KR1020080028830 - siRNA FOR INHIBITING EXPRESSION OF NF-kB DIRECTLY AND AN AGENT FOR TREATING RHEUMATOID ARTHRITIS COMPRISING THE SAME AS AN EFFECTIVE INGREDIENT AND A PHARMACEUTICALLY ACCEPTABLE CARRIER

Office
République de Corée
Numéro de la demande 1020077006266
Date de la demande 19.03.2007
Numéro de publication 1020080028830
Date de publication 01.04.2008
Numéro de délivrance 1008486660000
Date de délivrance 28.07.2008
Type de publication B1
CIB
C12N 15/10
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
NMICRO-ORGANISMES OU ENZYMES; COMPOSITIONS LES CONTENANT; CULTURE OU CONSERVATION DE MICRO-ORGANISMES; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE; MILIEUX DE CULTURE
15Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
09Technologie d'ADN recombinant
10Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
NMICRO-ORGANISMES OU ENZYMES; COMPOSITIONS LES CONTENANT; CULTURE OU CONSERVATION DE MICRO-ORGANISMES; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE; MILIEUX DE CULTURE
15Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
09Technologie d'ADN recombinant
11Fragments d'ADN ou d'ARN; Leurs formes modifiées
Déposants BIONEER CORPORATION
(주)바이오니아
Inventeurs CHOI, YOUNG CHUL
최영철
PARK, HAN OH
박한오
CHOUNG, SO RIM
정소림
KIM, SEON HOE
김선회
KIM, JI YOUNG
김지영
LEE, EUN JU
이은주
LEE, MI YOUNG
이미영
KIM, YOUNG JOO
김영주
LEE, UI JIN
이의진
HAN, CHANG WHAN
한창환
Mandataires 이한영
Données relatives à la priorité 1020060025078 17.03.2006 KR
Titre
(EN) siRNA FOR INHIBITING EXPRESSION OF NF-kB DIRECTLY AND AN AGENT FOR TREATING RHEUMATOID ARTHRITIS COMPRISING THE SAME AS AN EFFECTIVE INGREDIENT AND A PHARMACEUTICALLY ACCEPTABLE CARRIER
(KO) NF-k B의 발현을 억제하는 s i RNA
Abrégé
(EN)
PURPOSE: A therapeutic agent for rheumatoid arthritis is provided to inhibit expression of NF-κB/RelA directly in a genetic level by comprising an siRNA with the inhibitory activity on NF-κB/RelA expression and induce abnormally proliferated apoptosis of synovial cells, thereby being widely utilized for treating the rheumatoid arthritis more effectively. CONSTITUTION: An siRNA comprises at least one sequence described as SEQ ID : NOs. 1 to 30 which is bound to an mRNA transcripted from a gene encoding NF-κB/RelA in vivo to inhibit expression of the NF-κB/RelA. The siRNA is characterized in that it further includes a 3' overhang having one or two unpaired nucleotide(s) at a 3'-terminal of the sequence and each of the nucleotide of the sequence is 2'-O-methyl or phosphorothioate introduced thereinto. A therapeutic agent for rheumatoid arthritis comprises the siRNA as an effective ingredient and a pharmaceutically acceptable carrier. ©KIPO 2008

(KO)
본 발명은 NF-kB/RelA의 발현을 억제하는 siRNA 및 전기 siRNA를 유효성분으로 포함하는 류마티스 관절염 치료제에 관한 것이다. 본 발명의 류마티스 관절염 치료제는 세포내에서 NF-kB/RelA를 암호화하는 유전자로부터 전사된 mRNA와 결합하여 NF-kB/RelA 발현을 억제할 수 있는 siRNA를 유효성분으로 포함한다. 본 발명의 류마티스 관절염 치료제는 유전자 수준에서 NF-kB/RelA의 발현을 직접적으로 억제할 수 있을 뿐만 아니라, 비정상적으로 증식하는 활막세포의 사멸을 유도할 수 있으므로, 보다 효과적인 류마티스 관절염의 치료에 널리 활용될 수 있을 것이다.

Related patent documents